EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MEKICS Co Ltd (058110) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of MEKICS Co Ltd KRW 1,581, price KRW 1,499, upside +5.5%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7058110008

MC Thin data Oct 3, 2026

MEKICS Co Ltd

058110 · KQ

Low PriorityFair Value upside is limited and quality is weak.

Low debt
Fair value 1,581 KRW · Fairly valued (+5.5%)
Quality 46/100
Thin margins · 3.2% net margin (TTM)
Weak Growth (revenue 5y −30.2 %/yr in KRW)
Negative free cash flow
Trails peers (1/7)
Narrow moat 16/100
Thin data
Watch MEKICS Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,753 KRW 1,451 KRW Fair Value 1,581 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,451 KRW – 16,753 KRW · fair‑value band 1,180 KRW – 2,360 KRW · the 1,499 KRW price screens below the 1,581 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow MEKICS Co in your weekly email

Every Wednesday you see whether MEKICS Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products. The company also distributes CPAP solutions that care sleep apnea syndrome and snoring.

Show more

MEKICS CO., Ltd develops and commercializes ventilators worldwide. It offers general-purpose ventilators, respiratory care devices, patient monitoring systems, pulse oximeter, central monitoring system, and high flow nasal therapy products. The company also distributes CPAP solutions that care sleep apnea syndrome and snoring. MEKICS CO., Ltd was founded in 1998 and is headquartered in Paju, South Korea.

Stock analysis

MEKICS Co Ltd (058110) currently trades at 1,499 KRW, while our model-based Fair Value estimate is 1,581 KRW, so the stock looks roughly fairly valued today (gap 5.2%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,180 KRW (bear) to 2,360 KRW (bull), the price of 1,499 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

MEKICS Co Ltd reported revenue of 11.3B KRW in FY2025 versus 49.3B KRW in FY2021, a compound −30.8%/yr. Reported net income was −2.5B KRW in FY2025.

Key figures

Market cap 23.2B KRW (≈ $17.3M) · P/S ratio 0.70 · Net margin −22.5% · Return on equity −2,189% · Return on assets (EBIT) −6.5% · Operating margin −2.8% · Revenue (TTM) 33.2B KRW · Revenue growth (YoY) −56.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 5%, 058110 screens cheaper than that median.

Fair Value models

Bear 1,180 KRW Fair Value 1,581 KRW Bull 2,360 KRW
Price 1,499 KRW · Upside +5.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,182 KRW 1,584 KRW 2,365 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,182 KRW 1,584 KRW 2,365 KRW 54

Open the full fair value analysis →

Notify me when 058110 reaches fair value

Put 058110 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 46 · Market factors (momentum, volatility) 22

Profitability 5
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 50
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 84
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.2%
Start year 2020 (pandemic). Over 10 years: +2.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
44.6% (2020) → −24.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 058110, get fair value alerts →

Compare MEKICS Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2366 stocks

Beats the sector median on 1/7 measures
Overall it trails its sector peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +5.5% · Above median
Profitability
Return on assets −0.6% · Below median
Net margin (TTM) 3.2% · Below median
Operating margin (TTM) −2.8% · Bottom 25%
Growth and dividend
Revenue growth −56.3% · Bottom 25%
Balance sheet
Debt / equity 0.11× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)41 · sector 5
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)0 · sector 15
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
InBody Co 041830 53,400 KRW 58,740 KRW +10%
Value Added Technology Co 043150 17,850 KRW 48,636 KRW +172%
Mediana Co 041920 10,130 KRW 5,424 KRW −46%
Meta Biomed Co 059210 3,670 KRW 8,232 KRW +124%
Sewoon Medical Co 100700 2,300 KRW 5,541 KRW +141%
INM INM 0.1095 PLN 0.0400 PLN −63%
Eli Lilly and Company LLY $1,157 $749.08 −35%
Johnson & Johnson, JNJ $264.74 $168.85 −36%
AbbVie Inc ABBV $261.59 $259.62 −1%
Roche Holding RO CHF 375.20 CHF 326.56 −13%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEKICS Co Ltd · Fair Value
1,581 KRW +5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "MEKICS Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/058110

Frequently asked questions

Is MEKICS Co Ltd (058110) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1,581 KRW versus a price of 1,499 KRW, about +5% upside (fairly valued).
What is the fair value of 058110?
Our model-based fair value for MEKICS Co Ltd is 1,581 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 1,499 KRW.
What is the quality score of 058110?
MEKICS Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEKICS Co Ltd (058110)?
Our model-based price target is the fair value of 1,581 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 1,180 KRW, optimistic scenario 2,360 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MEKICS Co Ltd stock forecast for 2026?
Our models put fair value at 1,581 KRW, about +5% upside versus a price of 1,499 KRW (fairly valued). Cautious scenario 1,180 KRW, optimistic scenario 2,360 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MEKICS Co Ltd (058110)?
MEKICS Co Ltd reported trailing-twelve-month revenue of about 33.2B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of MEKICS Co Ltd (058110)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEKICS Co Ltd it is 1,581 KRW per share (as of Oct 3, 2026), against a price of 1,499 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MEKICS Co Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 058110 trades below its calculated fair value: price 1,499 KRW, fair value 1,581 KRW, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 058110?
No. The price is what the market pays today (1,499 KRW); the fair value is what the company's own numbers justify (1,581 KRW). For MEKICS Co Ltd the two are 82.32 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MEKICS Co Ltd worth?
The market values MEKICS Co Ltd at about 23.2B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 1,499 KRW; our models calculate a fair value of 1,581 KRW per share.
What do the bullish and bearish scenarios say about 058110?
Our models span a range for MEKICS Co Ltd: cautious scenario 1,180 KRW, base 1,581 KRW, optimistic 2,360 KRW per share (as of Oct 3, 2026, price 1,499 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MEKICS Co Ltd (058110)?
Balance-sheet figures for MEKICS Co Ltd (as of Oct 3, 2026): debt of 0.11 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 058110 from its 52-week high?
MEKICS Co Ltd trades at 1,499 KRW, about 57% below its 52-week high of 3,460 KRW and 3% above the low of 1,451 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 1,581 KRW is for.
Which stocks are comparable to MEKICS Co Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEKICS Co Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 1,499 KRW, calculated fair value 1,581 KRW (+5%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 058110 calculated?
We run MEKICS Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,581 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. MEKICS Co Ltd currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEKICS Co Ltd (058110)?
The closing price on Oct 2, 2026 was 1,499 KRW. Our model-based fair value is 1,581 KRW, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEKICS Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (1,180 KRW to 2,360 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of MEKICS Co Ltd

How large is the market capitalisation of MEKICS Co Ltd (058110)?
The market capitalisation of MEKICS Co Ltd is 23.2B KRW (≈ $17.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEKICS Co Ltd (058110)?
The price-to-sales ratio of MEKICS Co Ltd is 0.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of MEKICS Co Ltd (058110)?
The net margin of MEKICS Co Ltd is −22.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEKICS Co Ltd (058110)?
The return on equity (ROE) of MEKICS Co Ltd is −2,189% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEKICS Co Ltd (058110)?
On an EBIT basis the return on assets of MEKICS Co Ltd is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEKICS Co Ltd (058110)?
The operating margin of MEKICS Co Ltd is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEKICS Co Ltd (058110)?
Revenue at MEKICS Co Ltd is growing −56.3% versus a year earlier (3y avg −26.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEKICS Co Ltd (058110)?
Earnings per share at MEKICS Co Ltd are growing +4.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does MEKICS Co Ltd (058110) generate?
The free cash flow of MEKICS Co Ltd is −2.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MEKICS Co Ltd (058110) carry?
The net debt of MEKICS Co Ltd is 12.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MEKICS Co Ltd in the live analysis

One click puts MEKICS Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.